74 Chapter 3 1. Labzin LI, et al. Innate Immunity and Neurodegeneration. Annu Rev Med. Jan 29 2018;69:437-449. doi:10.1146/annurevmed-050715-104343 2. Banati RB, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. Nov 2000;123 ( Pt 11)(11):2321-37. doi:10.1093/brain/123.11.2321 3. Colasanti A, et al. In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18) F-PBR111 PET. J Nucl Med. Jul 2014;55(7):1112-8. doi:10.2967/jnumed.113.135129 4. Venneti S, et al. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. Dec 2006;80(6):308-22. doi:10.1016/j. pneurobio.2006.10.002 5. Bae KR, et al. Translocator protein 18 kDa negatively regulates inflammation in microglia. J Neuroimmune Pharmacol. Jun 2014;9(3):424-37. doi:10.1007/s11481-014-9540-6 6. Gottfried-Blackmore A, et al. Brain microglia express steroid-converting enzymes in the mouse. J Steroid Biochem Mol Biol. Mar 2008;109(1-2):96107. doi:10.1016/j.jsbmb.2007.12.013 7. Karlstetter M, et al. Translocator protein (18 kDa) (TSPO) is expressed in reactive retinal microglia and modulates microglial inflammation and phagocytosis. J Neuroinflammation. Jan 8 2014;11:3. doi:10.1186/1742-2094-11-3 8. Owen DR, et al. Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. Journal of Cerebral Blood Flow & Metabolism. 2017;37(8):2679-2690. 9. Wang M, et al. Macroglia-microglia interactions via TSPO signaling regulates microglial activation in the mouse retina. J Neurosci. Mar 5 2014;34(10):3793806. doi:10.1523/JNEUROSCI.3153-13.2014 10. Olah M, et al. Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer’s disease. Nat Commun. Nov 30 2020;11(1):6129. doi:10.1038/s41467-020-197372 11. Nutma E, et al. A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis. Brain. Nov 1 2019;142(11):34403455. doi:10.1093/brain/awz287 12. Polman CH, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. Dec 2005;58(6):840-6. doi:10.1002/ ana.20703 13. van der Valk P, et al. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol. Feb 2000;26(1):2-10. doi:10.1046/j.1365-2990.2000.00217.x 14. Ferreira TA, et al. Neuronal morphometry directly from bitmap images. Nat Methods. Oct 2014;11(10):982-4. doi:10.1038/nmeth.3125 15. Ghasemi A, et al. Normality tests for statistical analysis: a guide for non-statisticians. Int J Endocrinol Metab. Spring 2012;10(2):486-9. doi:10.5812/ijem.3505 16. Kim TK. Understanding one-way ANOVA using conceptual figures. Korean J Anesthesiol. Feb 2017;70(1):22-26. doi:10.4097/kjae.2017.70.1.22 17. Lee S, et al. What is the proper way to apply the multiple comparison test? Korean J Anesthesiol. Oct 2018;71(5):353-360. doi:10.4097/kja.d.18.00242 18. Peferoen LA, et al. Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis. J Neuropathol Exp Neurol. Jan 2015;74(1):48-63. doi:10.1097/NEN.0000000000000149 19. Zrzavy T, et al. Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis. Brain. Jul 1 2017;140(7):1900-1913. doi:10.1093/brain/awx113 20. Satoh J, et al. TMEM119 marks a subset of microglia in the human brain. Neuropathology. Feb 2016;36(1):39-49. doi:10.1111/neup.12235 21. Beckers L, et al. Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration. Mol Imaging Biol. Feb 2018;20(1):94-102. doi:10.1007/ s11307-017-1099-1 22. Banati RB, et al. PK (‘peripheral benzodiazepine’)- -binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol. Feb 1997;26(2):77-82. doi:10.1023/a:1018567510105 23. Debruyne JC, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol. May 2003;10(3):257-64. doi:10.1046/ j.1468-1331.2003.00571.x 24. Datta G, et al. (11)C-PBR28 and (18)F-PBR111 DetectWhiteMatter Inflammatory Heterogeneity in Multiple Sclerosis. J NuclMed. Sep2017;58(9):14771482. doi:10.2967/jnumed.116.187161 25. Unterrainer M, et al. TSPO PET with [(18)F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis. Eur J Nucl Med Mol Imaging. Jul 2018;45(8):14231431. doi:10.1007/s00259-018-3974-7 26. Vomacka L, et al. TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI Res. Oct 26 2017;7(1):89. doi:10.1186/s13550-017-0340-x 27. Kaunzner UW, et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain. Jan 1 2019;142(1):133-145. doi:10.1093/brain/awy296 References
RkJQdWJsaXNoZXIy MTk4NDMw